Mirna Therapeutics, a clinical-stage biotech developing microRNA replacement therapies for cancer, filed on Monday with the SEC to raise up to $81 million in an initial public offering.
The Austin, TX-based company, which was founded in 2007, plans to list on the Nasdaq under the symbol MIRN. Mirna Therapeutics initially filed confidentially on March 12, 2014. Citi and Leerink Partners are the joint bookrunners on the deal. No pricing terms were disclosed.
